PMID- 17500306
OWN - NLM
STAT- MEDLINE
DCOM- 20070710
LR  - 20170214
IS  - 0706-7437 (Print)
IS  - 0706-7437 (Linking)
VI  - 52
IP  - 4
DP  - 2007 Apr
TI  - Efficacy and safety of antidepressants for treatment of depression in Alzheimer's 
      disease: a metaanalysis.
PG  - 248-55
AB  - OBJECTIVE: Depression in patients with Alzheimer's disease (AD) is common (15% to 
      63%) and is associated with significant morbidity and increased mortality. Our 
      objective was to quantitatively summarize the data on the efficacy and safety of 
      antidepressant treatment for depression complicating AD. METHOD: We performed a 
      metaanalysis of randomized, double-blind, placebo-controlled trials of 
      antidepressants with a database search of the English literature (up to 2006) and 
      a manual search of references in the retrieved articles. We extracted the 
      proportion of subjects who responded and remitted, experienced adverse events 
      (AEs), discontinued treatment due to AEs, or discontinued treatment for any 
      reason. Cognition scores were also extracted. RESULTS: We included 5 studies, 
      which involved 82 subjects treated with antidepressants and 83 subjects who 
      received placebo treatment. Antidepressants were superior to placebo for both 
      treatment response (odds ratio [OR] 2.32; 95% confidence interval [CI], 1.04 to 
      5.16) and remission of depression (OR 2.75; 95% CI, 1.13 to 6.65). There were no 
      significant differences between the 2 groups for change in cognition (weighted 
      mean difference -0.71, 95% CI, -3.20 to 1.79), overall dropouts (OR 0.70; 95% CI, 
      0.29 to 1.66) or dropout due to AEs (OR 1.41; 95% CI 0.36 to 5.54). The numbers 
      needed to treat for one additional AD patient to respond to antidepressant 
      treatment were 5 (95% CI, 3 to 59) and 5 (95% CI, 2 to 24) for remission of 
      depression. CONCLUSIONS: Antidepressant treatment for depression in AD is 
      efficacious, with rates of discontinuation that are comparable to placebo. 
      Nonetheless, clinicians must be vigilant regarding the potential side effects of 
      antidepressants in this population.
FAU - Thompson, Sarah
AU  - Thompson S
AD  - Department of Psychiatry, Atlantic Health Sciences Corporation, Saint John, New 
      Brunswick.
FAU - Herrmann, Nathan
AU  - Herrmann N
FAU - Rapoport, Mark J
AU  - Rapoport MJ
FAU - Lanctot, Krista L
AU  - Lanctot KL
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Can J Psychiatry
JT  - Canadian journal of psychiatry. Revue canadienne de psychiatrie
JID - 7904187
RN  - 0 (Antidepressive Agents)
SB  - IM
CIN - Evid Based Ment Health. 2007 Nov;10(4):115. PMID: 17962667
MH  - Aged
MH  - Alzheimer Disease/*epidemiology
MH  - Antidepressive Agents/*adverse effects/therapeutic use
MH  - Depressive Disorder, Major/*drug therapy/*epidemiology
MH  - Humans
MH  - Randomized Controlled Trials as Topic
EDAT- 2007/05/16 09:00
MHDA- 2007/07/11 09:00
CRDT- 2007/05/16 09:00
PHST- 2007/05/16 09:00 [pubmed]
PHST- 2007/07/11 09:00 [medline]
PHST- 2007/05/16 09:00 [entrez]
AID - 10.1177/070674370705200407 [doi]
PST - ppublish
SO  - Can J Psychiatry. 2007 Apr;52(4):248-55. doi: 10.1177/070674370705200407.